IRADIMED CORP
About IRADIMED CORP
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $83.8M
- Net income
- $22.5M
- Total assets
- $108.8M
- Market cap
- $1.2B
- Gross margin
- 76.7%
- Operating margin
- 31.2%
- Net margin
- 26.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $83.8M
- Cost of revenue
- $19.5M
- Gross profit
- $64.3M
- Operating expenses
- $38.2M
- Operating income
- $26.1M
- Income tax
- $5.9M
- Net income
- $22.5M
- EPS (basic)
- $1.77
- EPS (diluted)
- $1.75
Balance sheet
- Total assets
- $108.8M
- Current assets
- $81.2M
- Total liabilities
- $14.2M
- Current liabilities
- $10.2M
- Shareholders’ equity
- $94.6M
Cash flow
- Operating cash flow
- $24.9M
- Investing cash flow
- -$8.4M
- Financing cash flow
- -$17.6M
- Net cash flow
- -$1.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.2B
- P/E ratio
- 53.9
- EPS (diluted)
- $1.75
- Dividend yield
- 0.85%
- Shares outstanding
- 12.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 16, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $22.5M in FY2025.
- Revenue grew 100% from FY2021 to FY2025.
- Gross margin of 76.7%, net margin 26.8%.
- Trading 10% below its 52-week high.
- Pays a dividend yielding about 0.85% annually.
- Valued at a price-to-earnings (P/E) ratio of 53.9.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review IRADIMED CORP.
Write a review
News about IRADIMED CORP
News & sentiment via Polygon.io
